Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

Abstract

Efficacy of EFGR TKIs Monotherapy in Comparison with Standard Second-line Chemotherapy for Advanced NSCLCAsian Pacific J Cancer Prev, 13 (10), 5177-5182 IntroductionLung cancer is still a leading cause of cancer-related deaths worldwide with a 5-year survival of less than 15% (Parkin et al., 2002;Schiller et al., 2002;. Because the majority of people diagnosed with non-small cell lung cancer (NSCLC) are unsuitable for surgery, chemotherapy remains the cornerstone of treatment and prolongs survival with a positive impact on quality of life. However, the majority of patients with advanced NSCLC experience cancer progression after 3-6 months of first-line chemotherapy, and approximately 40% of them have progressive disease during the treatment

Relationship between Epidermal Growth Factor Receptor Gene Mutations and Clinicopathological Features in Patients with Non-Small Cell Lung Cancer in Western Turkey

“…Nowadays, the important target of these drugs is EGFR. Drugs like erlotinib and gefitinib which target EGFR have achieved higher response rates (Pao et al, 2004;Qi et al, 2012;Saito et al, 2012). In NSCLC, EGFR mutation is identified by typical deletion in exon 19, point mutation in exon 21, and extensive insertion in exon 21, among them the mostly widely known type is exon 19 deletion (Tokumo et al, 2005).…”

Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer

“…Nonsmall cell lung cancer (NSCLC) accounts for about 80% of lung cancer cases and most are diagnosed at advanced stages (Lal et al, 2011;Kirmani et al, 2013). Tailored therapy based on biomarker analysis has entered the reality of lung cancer treatment (Qi et al, 2012;Gridelli et al, 2014). Patients with EGFR activated mutation or ALK/ ROS1 fusion benefit from targeted therapy with EGFR TKIs or ALK inhibitors (Gao et al, 2012).…”

Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials

“…Although the prognosis is much better with early detection, over 70% of NSCLC patients present with advanced disease and the 5 year survival rate for NSCLC is 16% 4,5 . During the past few decades, therapies for advanced NSCLC have significantly changed due to the use of several epidermal growth factor receptor (EGFR) targeted agents and angiogenesis inhibitors that have radically modified the natural history of this pathology [6][7][8][9][10][11][12] .…”